Arcutis Biotherapeutics Files 8-K
Ticker: ARQT · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $9.50, $161.6 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K, disclosure
Related Tickers: ARQT
TL;DR
ARQT filed an 8-K on 2/28, updating corporate info. Nothing major, just housekeeping.
AI Summary
Arcutis Biotherapeutics, Inc. filed an 8-K on February 28, 2024, reporting other events and financial statements. The filing details the company's corporate structure and its principal executive offices located at 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361. The company was incorporated in Delaware and operates under the Pharmaceutical Preparations SIC code.
Why It Matters
This 8-K filing provides essential corporate information and updates for Arcutis Biotherapeutics, Inc., which is crucial for investors and stakeholders to understand the company's operational and legal standing.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information about significant financial events, acquisitions, or legal issues that would typically increase risk.
Key Numbers
- 001-39186 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-2974255 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Arcutis Biotherapeutics, Inc. (company) — Registrant
- February 28, 2024 (date) — Date of Report
- 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361 (location) — Principal executive offices
- Delaware (jurisdiction) — State of incorporation
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What is the primary purpose of this 8-K filing for Arcutis Biotherapeutics, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of February 28, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 28, 2024.
Where are Arcutis Biotherapeutics, Inc.'s principal executive offices located?
The principal executive offices of Arcutis Biotherapeutics, Inc. are located at 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361.
In which state was Arcutis Biotherapeutics, Inc. incorporated?
Arcutis Biotherapeutics, Inc. was incorporated in Delaware.
What is the Standard Industrial Classification (SIC) code for Arcutis Biotherapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Arcutis Biotherapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 945 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-03-04 16:10:37
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ARQT The Nasdaq Global Select
- $9.50 — at a public offering price per share of $9.50 (the "Offering"). Under the terms of th
- $161.6 m — ds from the Offering were approximately $161.6 million, after deducting underwriting dis
Filing Documents
- arqt-20240228.htm (8-K) — 31KB
- exhibit11-closing8xk.htm (EX-1.1) — 215KB
- exhibit51-closing8xk.htm (EX-5.1) — 19KB
- lathama.jpg (GRAPHIC) — 14KB
- 0001628280-24-008496.txt ( ) — 464KB
- arqt-20240228.xsd (EX-101.SCH) — 2KB
- arqt-20240228_lab.xml (EX-101.LAB) — 24KB
- arqt-20240228_pre.xml (EX-101.PRE) — 13KB
- arqt-20240228_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated February 28, 2024, by and among Arcutis Biotherapeutics, Inc. and Morgan Stanley & Co. LLC, Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein . 5.1 Opinion of Latham & Watkins LLP. 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1) . 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUTIS BIOTHERAPEUTICS, INC. Date: March 4, 2024 By: /s/ John W. Smither John W. Smither Chief Financial Officer